POMDOCTOR Reports Widened FY2025 Net Loss of $18.7M, Operating Cash Burn of $21.2M; IPO Proceeds Consumed

summarizeSummary

POMDOCTOR Ltd reported a significantly widened net loss and massive operating cash burn for fiscal year 2025, with IPO proceeds quickly consumed, leading to a critically low cash balance.

check_boxKey Events · Earnings and Guidance · POM

• Net Loss Widened Significantly

  Net loss increased to US$18.7 million in fiscal year 2025, compared to US$37.4 million in fiscal year 2024, primarily due to IPO-related expenses.

• Operating Cash Burn Surged

  Net cash used in operating activities dramatically increased to US$21.2 million in fiscal year 2025, up from US$16.1 million in the prior year.

• Critically Low Cash Reserves

  The company ended fiscal year 2025 with only US$1.4 million in cash and cash equivalents, insufficient to cover its burn rate.

• IPO Proceeds Consumed

  Gross proceeds of US$23 million from the October 2025 IPO were largely consumed by operating losses and professional service fees related to the offering.

auto_awesomeAnalysis · POM · Trade & Services

This filing details the financial results that underpin the going concern warning and Nasdaq delisting notice disclosed in the concurrent 20-F filing. The company's net loss significantly widened to $18.7 million, and operating cash burn surged to $21.2 million in fiscal year 2025. These figures are larger than the company's entire market capitalization, indicating severe financial distress. Despite raising $23 million in an IPO in October 2025, the company ended the year with only $1.4 million in cash, suggesting the IPO proceeds were largely consumed by operating losses and IPO-related expenses, failing to provide a sustainable cash runway.